White Paper Summary Once considered novel, it is now widely accepted that Social Determinants of Health (SDoH)—such as financial stability, health literacy, race, and ethnicity—influence up to 80% of health outcomes. 1 To date, most initiatives to attenuate the impact of SDoH have been led by health systems or health plans, emphasizing improving access, addressing quality disparities, supporting population management, and informing the point of care. But life sciences firms also have a role to play, particularly in addressing the underrepresentation of diverse populations in clinical trials. Clinical Trials are often not accessible in many communities that could provide an eligible and diverse patient base. Beyond the obvious human impacts, there are downstream negative impacts

Join for free to read